The Chicago Mercantile Exchange's ( CME) profit rose 35%, fueled by higher trading of foreign exchange and commodity products.

The futures and commodity exchange beat analysts' earnings expectations by 6 cents a share. In the fourth quarter, the CME made $102.6 million, or $2.91 a share, compared to $76.2 million, or $2.18 a share, a year earlier.

But revenue, which rose 26% from a year earlier, to $281.3 million, fell below analysts' expectations of $286.8 million.

In the quarter, clearing and transaction fees rose 25%, to $219.7 million. The CME said higher clearing fees were a result of a 29% jump in average daily trading volume to 5.3 million contracts. Specifically higher volume in foreign exchange products, interest rate products, CME E-mini products and commodity products fueled the rise.

The CME said electronic trading made up 75% of total trading volume last year.

Revenue from processing services, in which the CME supports the Chicago Board of Trade ( BOT) and the New York Mercantile Exchange ( NMX) among others surged 79% from the year-ago quarter, to $28 million.

Expenses rose 15%, to $123 million.

For the year, the exchange made $407 million, or $11.60 a share, an increase of 33% from 2005.

The exchange's $8 billion deal for the Chicago Board of Trade is expected to close around midyear after receiving shareholder and regulatory approval. The deal will create CME Group, a trading powerhouse for derivatives and future contracts, valued at $25 billion, with an average daily trading volume of about 9 million contracts.

More from Stocks

Banks Prepare to Up Shareholder Payouts By $30 Billion

Banks Prepare to Up Shareholder Payouts By $30 Billion

Starbucks Just Revealed Some of the Most Worrying Data in Its History

Starbucks Just Revealed Some of the Most Worrying Data in Its History

Dow Plunges on Trade War Worries but Walmart and Verizon Finish Positively

Dow Plunges on Trade War Worries but Walmart and Verizon Finish Positively

Trump's Tariff Attack Hasn't Brought Pain to These Hot Stocks

Trump's Tariff Attack Hasn't Brought Pain to These Hot Stocks

Biotech Firm Sarepta Surges 40% on Positive Test Results

Biotech Firm Sarepta Surges 40% on Positive Test Results